The U.S. Food and Drug Administration (FDA) said on Tuesday it would review Pfizer Inc's request to authorize booster doses of COVID-19 vaccine in all adults 'as expeditiously as possible,' with the New York Times reporting that the regulatory nod could come as soon as Thursday.
The agency said it does not plan to hold a meeting of the outside experts on Pfizer's request, concluding the request does not raise questions that would benefit from additional discussion by the members of the committee.
Earlier this month, Pfizer had requested the FDA to authorize booster doses of the vaccine in all adults, presenting recent data showing the shot would help prevent disease across ages. U.S. President Joe Biden's administration in August announced plans to roll out booster doses for all adults in September.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer asks FDA to authorize Covid antiviral pillsPfizer asked the FDA to authorize its oral Covid antiviral pill called Paxlovid. The treatment is highly effective in reducing the risk of hospitalization.
Lire la suite »
Pfizer Seeks FDA Emergency Use Authorization for Its COVID-19 PillPfizer has signed a deal to allow other manufacturers to make its experimental COVID-19 pill, possibly opening up access to treatment to countries across the world:
Lire la suite »
Pfizer seeks FDA emergency use authorization for its experimental Covid-19 antiviral pillPfizer announced Tuesday that it is seeking emergency use authorization from the US Food and Drug Administration for its experimental antiviral Covid-19 pill, known as PF-07321332 or Paxlovid.
Lire la suite »
FDA expected to authorize Pfizer COVID-19 booster for all adults this weekThe move could come as early as Thursday.
Lire la suite »